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ABSTRACT
We investigated the adhesive behavior of mesenchymal stem cells (MSC) in blood, which might
inﬂuence their fate when infused as therapy. Isolated human bone marrow MSC (BMMSC) or
umbilical cord MSC (UCMSC) adhered efﬁciently from ﬂow to the matrix proteins, collagen, or
ﬁbronectin, but did not adhere to endothelial selectins. However, when suspended in blood,
BMMSC no longer adhered to collagen, while UCMSC adhered along with many aggregated
platelets. Neither MSC adhered to ﬁbronectin from ﬂowing blood, although the ﬁbronectin
surface did become coated with a platelet monolayer. UCMSC induced platelet aggregation in
platelet rich plasma, and caused a marked drop in platelet count when mixed with whole
human or mouse blood in vitro, or when infused into mice. In contrast, BMMSC did not
activate platelets or induce changes in platelet count. Interestingly, isolated UCMSC and BMMSC
both adhered to predeposited platelets. The differences in behavior in blood were attributable
to expression of podoplanin (an activating ligand for the platelet receptor CLEC-2), which was
detected on UCMSC, but not BMMSC. Thus, platelets were activated when bound to UCMSC,
but not BMMSC. Platelet aggregation by UCMSC was inhibited by recombinant soluble CLEC-2,
and UCMSC did not cause a reduction in platelet count when mixed with blood from mice deﬁ-
cient in CLEC-2. We predict that both MSC would carry platelets in the blood, but their interac-
tion with vascular endothelium would depend on podoplanin-induced activation of the bound
platelets. Such interactions with platelets might target MSC to damaged tissue, but could also
be thrombotic. STEM CELLS 2018; 00:000–000
SIGNIFICANCE STATEMENT
Mesenchymal stem cells (MSC) may be used to for therapy by injection into the blood. How-
ever, little is known about the behavior of MSC in flowing blood and subsequent adhesion in
blood vessels. This study shows that the adhesive behavior of flowing MSC depends on their
origin because this influences how they interact with platelets also found in the blood. MSC
from umbilical cords induce platelet activation which could cause clots to form. The platelets
also influence how all MSC stick to surfaces, which could affect their deposition in damaged tis-
sues. The results have implications for therapeutic infusion of MSC.
INTRODUCTION
Mesenchymal stem cells (MSC) are multipotent
stem-like cells extracted ﬁrst from the bone
marrow (BM), but recently also obtained from
umbilical cords (UCs) and adipose tissue [1].
MSC have the ability to repair damaged tissue
[2]. For instance, administration of bone-marrow
mesenchymal stem cells (BMMSC) improved the
outcome in animal models of chronic cardiac
ischemia and acute myocardial infarction [3–5].
The mechanisms underlying the therapeutic
beneﬁts of MSC are not well understood, but it
is believed that MSC promote tissue growth and
wound healing, and modulate immune responses
[6, 7]. Immunosuppressive effects of MSC include
induction of apoptosis of activated T cells [8],
expansion of immunosuppressive Tregs [9, 10],
suppression of monocyte differentiation into
dendritic cells [11], and cross-talk with endo-
thelial cells to downregulate recruitment of
leukocytes [8].
Consequently, MSC have been widely used
in clinical trials, in which they are commonly
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administered by intravenous injection [12]. The recruitment of
circulating MSC into the target tissue remains poorly under-
stood, but may be critical for therapeutic efﬁcacy [13]. When
delivered systemically, MSC have been found at sites of injury,
suggesting that circulating MSC may target damaged tissue
[14]. However, MSC have a larger diameter than the pulmo-
nary capillaries, which may cause trapping in the lungs and
prevent access to the intended organs [15]. Nevertheless, it
has been suggested that like leukocytes, MSC go through a
multistep process to cross the endothelium [16], with initial
capture supported by P-selectin [17]. However, we and others
have only observed attachment of MSC to endothelial cells
from ﬂow at very low shear stress [14, 18]. Several studies
indicate that platelets could play a role in MSC recruitment.
Intravascular infused MSC were observed in contact with
neutrophil-platelet clusters in inﬂamed ear dermis [19]. In a
rat model of pulmonary arterial hypertension, MSC deposition
in the lung was dependent on platelet activation and medi-
ated by P-selectin and platelet glycoprotein GPIIb/IIIa (aIIbb3-
integrin) [20]. It appears, therefore, that MSC are not efﬁcient
at binding to intact endothelium under circulatory conditions.
However, their ability to bind to exposed matrix proteins
under ﬂow and their adhesive behavior in ﬂowing whole
blood have not been directly analyzed. Moreover, the studies
outlined above have all used BMMSC and may not reﬂect the
behavior of MSC from other tissues.
The foregoing suggests that to understand the fate of
MSC in the circulation and optimize their therapeutic delivery,
we need to deﬁne their ability to adhere to different surfaces
in the presence of whole blood and the possible effects of tis-
sue origin on these interactions. To answer these questions,
BMMSC or umbilical cord mesenchymal stem cells (UCMSC)
were suspended in culture medium or in whole blood, per-
fused through glass capillaries coated with chosen adhesive
substrates and their adhesion assessed. We also investigated
MSC interactions with platelets in suspension (either puriﬁed
platelets or whole blood) and as a monolayer deposited on a
ﬁbronectin. Finally, we investigated the fate of MSC infused
into mice and their effects on platelet numbers in blood. We
observed differences in adhesive properties between BMMSC
and UCMSC, and especially in their interactions with platelets.
This was linked to differential expression of podoplanin, a
membrane glycoprotein expressed on some stromal cells as
well as lymphatic endothelial cells, and known to activate pla-
telets through its ligand CLEC-2 [21–25]. This study shows that
the origin of MSC and differences in their adhesive behavior
may have an impact on their therapeutic use.
METHODS
Ethics and Collection of Tissues
The study was conducted in compliance with the Declaration
of Helsinki. All human samples were obtained with written,
informed consent and approval from the Human Biomaterial
Resource Centre (Birmingham, U.K.), the West Midlands and
Black Country Research Ethics Committee, or University of
Birmingham Local Ethical Review Committee. All animal
experiments were performed under a Home Ofﬁce Project
License in accordance with UK legislation.
Blood was drawn by venepuncture from healthy adult
volunteers into citrate phosphate dextrose adenine (CPDA)
solution (1:9, blood vol/vol, Sigma-Aldrich, Poole, UK; https://
www.sigmaaldrich.com). Blood was drawn from mice via car-
diac puncture and anticoagulated with CPDA. UCs were col-
lected from anonymous donors with the assistance of the
Birmingham Women’s Health Care NHS Trust and Sandwell
and West Birmingham Hospitals NHS Trust.
Isolation, Culture, and Characterization of MSC
The methods of MSC isolation and culture were as described
recently [26, 27]. Human BMMSC were purchased from Lonza
and cultured in the manufacturer’s recommended medium
(Mesenchymal Stem Cells Growth Medium BulletKit, Lonza,
Ltd., Burton on Trent, UK; https://www.lonza.com/) and used
between passages 5 and 10. UCMSC were isolated from UCs
as previously described [26] and used between passages 3
and 10. For adhesion assays, MSC were dissociated by trypsin
EDTA solution, counted using a Cellometer (Nexcelom Biosci-
ence, Ltd., Lawrence, MA; https://www.nexcelom.com) and
suspended at 5 3 105/ml in culture medium.
Cells were identiﬁed as MSC based on the criteria of the
International Society for Cell Therapies [28]. Their ability to
differentiate into osteocytes, adipocytes, and chondrocytes,
their surface expression of CD44, CD73, CD90, CD105, and
CD146, and their lack of expression of CD14, CD20, CD34, and
CD45 were veriﬁed as recently described [26]. To test expres-
sion of b1-, b2-, and b3-integrins, MSC were incubated with
ﬂuorescein isothiocyanate (FITC)-conjugated anti-b1-integrin
(Clone B-D15; Abcam, Cambridge, UK; https://www.abcam.
com) or phycoerythrin (PE)-conjugated anti-b2-integrin (Clone
212701; R&D Systems, Abingdon, UK; https://www.rndsys-
tems.com), or with unconjugated anti-b3-integrin (SZ21; Beck-
man Coulter, Inc., High Wycombe, UK; https://www.
beckmancoulter.com) followed by incubation with FITC-
conjugated goat anti-mouse secondary antibody (Dako, Santa
Clara; https://www.agilent.com/). Expression of podoplanin
(PDPN) was analyzed using PE-conjugated anti-podoplanin
(clone NZ-1.3, eBioscience, Waltham, MA; https://www.
thermoﬁsher.com). Control samples were incubated with
isotype-matched nonspeciﬁc antibodies, either conjugated
appropriately or with secondary labeling as above. The level of
expression was evaluated using a Cyan ADP ﬂow cytometer.
Data were analyzed ofﬂine using Summit 4.3 (both Beckman
Coulter, Inc.). In some experiments, we fractionated MSC based
on the level of expression of podoplanin (i.e., PDPN1 and
PDPN2 cells) using a MoFlow Astrios cell sorter (Beckman) and
returned them to culture. Separated fractions, or fractions
within the original population (gated using PDPN expression),
were also reanalyzed for expression of MSC markers.
Adhesion of Flowing MSC to Purified Receptors or
Platelets
Adhesion of ﬂowing MSC to chosen substrates was analyzed
as recently described [8]. Microslides (glass capillaries with
rectangular cross-section of width W5 3.0 mm by depth
D5 0.3 mm) were coated by incubation for 2 hours at 378C
with required proteins in phosphate-buffered saline (PBS): 1%
bovine serum albumin (BSA), 10 lg/ml P-selectin; 100 lg/ml
E-selectin; 20 lg/ml plasma ﬁbronectin (all from Sigma); 500
mg/ml equine tendon collagen (Horm collagen; Axis-Shield,
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Dundee, U.K., https://www.axis-shield.com/). Microslides were
ﬂushed with 1% BSA and incubated overnight at 48C to block
nonspeciﬁc protein binding sites.
Microslides were attached to a perfusion system and
mounted onto the stage of a phase-contrast and ﬂuorescence
video-microscope, and events recorded as described [8, 27].
Cell-free buffer or MSC were drawn through the microslide at
chosen ﬂow rate (Q) and hence wall shear rate (cw), calcu-
lated from the equation cw5 6Q/(W D
2). UCMSC or BMMSC
at 5 3 105/ml were ﬂowed over the different surfaces for 4
minutes. The MSC were either suspended in culture medium
(as described above) or in whole blood. In the latter case,
MSC in culture medium (1 ml at 5 3 105/ml) were centri-
fuged, the supernatant removed and the cell pellet resus-
pended in 1 ml blood. When using blood, MSC were ﬁrst
stained with Cell Tracker Green (5 mM; Life Technologies, Wal-
tham MA; https://www.thermoﬁsher.com). Nonadherent cells
were washed from the microslide using cell-free medium and
video recordings were made of a series of microscope ﬁelds
along the centerline of the microslide and analyzed ofﬂine.
Adherent cells were counted and converted to a percentage
of all MSC perfused to obtain a value for efﬁciency of attach-
ment corrected for ﬂow rate and hence number perfused, as
described previously [8].
To assess MSC binding to immobilized platelets, whole blood
was perfused through a microslide coated with ﬁbronectin for 4
minutes at a wall shear rate of 35 s21. The microslide was then
washed out with PBS without Ca21 and Mg21 so that a platelet
monolayer was left on the surface. When desired, to fully acti-
vate the deposited platelets, 10 lM thrombin receptor activating
peptide (TRAP; Abcam) was then added for 30 minutes.
In some experiments, MSC were pretreated with function-
blocking antibodies against adhesion receptors or antibodies
against platelet-receptors were added to the blood for 10
minutes at room temperature at a concentration of 10 mg/ml
before perfusion. Antibodies were against: b1-integrin (mab13;
BD Pharmingen, Wokingham, UK; https://www.bdbiosciences.
com/); b3-integrin (SZ21; Beckman Coulter); aIIbb3-integrin
(Abciximab; Eli Lilly: Hampshire, U.K., https://www.lilly.co.uk/);
GPIb (SZ1; Beckman Coulter).
Aggregation of Platelets Induced by MSC
Platelet-rich plasma (PRP) was harvested from blood centri-
fuged at 300g for 5 minutes and platelet-poor plasma (PPP)
after further centrifugation at 1,500g for 15 minutes. Seventy
microliter of BMMSC or UCMSC at a concentration of 1.5 3
106/ml was added to 280 ml of PRP and mixed for 20 minutes
on a roller mixer in a 378C incubator. The samples were ana-
lyzed using a spectrophotometer (Biotec, Bridport, Dorset,
U.K., https://biotec.com/) which measured the light absor-
bance (or turbidity) at 540 nm of PRP (PRPabs) and platelet-
poor plasma (PPPabs), compared to PRP mixed with MSC
(MSCabs). In general, the absorbance of PRP decreases when
the platelets aggregate, with a minimum being absorbance of
PPP. Here, effects of MSC were quantiﬁed as absorbance rela-
tive to PRP, calculated as: (MSCabs2 PPPabs)/(PRPabs2
PPPabs)3 100%. Thus, an absorbance of 100% would indicate
no effect of the MSC, while reduction would signify increasing
aggregation, down to a relative absorbance of 0% (equal to
PPP and thus equivalent to removing all platelets). In some
experiments, UCMSC were pretreated with antibody against
b1-integrin, or antibody against aIIbb3-integrin was added to
PRP, or human recombinant CLEC-2 protein (30 mg/ml; R&D
systems, Abingdon, U.K.) was added to MSC and PRP.
Effect of MSC on Platelet Count in Blood
BMMSC or UCMSC (2.5 3 105) were centrifuged at 400g for 5
minutes and the pellet resuspended in 1 ml of human or murine
blood and placed on a roller mixer at 378C for 20 minutes, along
with an aliquot of whole blood. Platelet counts were obtained
with an ABX Pentra 60 (ABX Diagnostics, Irvine, CA, https://www.
horiba.com/). Blood smears were made and stained with hema-
toxylin and eosin (H&E; Leica, Milton Keynes, UK; https://www.
leicabiosystems.com) and examined by light microscope. We
compared blood from 8 to 12-week-old platelet-speciﬁc CLEC-2
deﬁcient mice, Clec1bﬂ/ﬂPF4-Cre, and their matched controls,
Clec1bﬂ/ﬂ [8].
MSC Infusion into Mice—Localization and Effects on
Platelet Count
Wild-type male and female C57/BL6 mice at the age 8–12
weeks were obtained from the Charles Rivers Laboratories
(Margate, U.K.; https://guide.labanimal.com/supplier/charles-
river-uk-ltd). CLEC-2 deﬁcient mice and matched controls were
as described above. BMMSC or UCMSC (2.5 3 105) were sus-
pended in 200 ml of PBS and injected into the tail vein. Con-
trol mice received 200 ml of PBS. Mice were bled via the tail
into CPDA for platelet counts 24 hours before MSC injection,
and 4, 24, 48, and 72 hours postinjection. The ﬁnal bleed was
obtained by cardiac puncture following neck dislocation on
isoﬂurane anesthetized animals. Platelet counts were mea-
sured using an ABX Pentra 60.
Alternatively, isolated BMMSC or UCMSC were labeled
with 0.3 mg/ml Xenolight DiR (Caliper Life Sciences, Preston
Brook, UK, https://www.caliperLS.com) for 30 minutes at
378C. Cells were washed three times in PBS and resuspended
in 200 ml of PBS for tail vein injection. Mice were culled 1-
hour post MSC injection and organs were isolated and imaged
using an “IVIS Spectrum In Vivo Imaging System” (Caliper Life
Sciences). Images were acquired by Epi-illumination at
745 nm excitation and 800 nm emission.
Statistical Analysis
Data are shown as mean6 SEM of (n) replicate experiments.
Statistical analysis was performed using Minitab 17 software
(Minitab, Inc., State College, PA). Effects of multiple conditions
were analyzed using analysis of variance and post hoc com-
parisons between treatments were made using Bonferroni
test. Single treatments were compared to control by paired or
unpaired t test as appropriate.
RESULTS
Comparison of Adhesion of UCMSC and BMMSC from
Flow
UCMSC and BMMSC were perfused over surfaces coated with
receptors that would be presented by activated platelets or
inﬂamed endothelium (P-selectin and E-selectin) or by dam-
aged vessel wall (collagen and ﬁbronectin), or with albumin
only. Adhesion to P-selectin, E-selectin, or albumin was barely
detectable; even at a low wall shear rate of 18 s21, <0.1% of
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perfused cells adhered. When UCMSC were ﬂowed over colla-
gen at a wall shear rate of 18 s21, around 30% adhered (Fig.
1A). Adhesion decreased with increasing shear rate (Fig. 1A).
Adhesion of UCMSC to ﬁbronectin showed a similar trend but
was, on average, lower than to collagen (Fig. 1B). When
BMMSC were perfused over the same surfaces, similar shear-
dependence of adhesion was observed, but overall, adhesion
was lower than that seen for UCMSC (Fig. 1). Doubling the
highest shear rate to 140 s21 essentially abolished adhesion
for either cell type.
Figure 1. Adhesion of ﬂowing UCMSC and BMMSC to collagen or ﬁbronectin: effect of wall shear rate and roles of integrins. (A, B): UCMSC
and BMMSC were perfused for 4 minutes over (A) collagen or (B) ﬁbronectin at wall shear rates of 18, 35, or 70 s21. In (A, B), analysis of
variance showed signiﬁcant effects of wall shear rate and of cell type (p< .01 in both cases). **, p< .01 by Bonferroni test. Data are mean6
SEM from three experiments. (C): Expression of b1-, b2-, and b3-integrins was assessed on BMMSC and UCMSC by ﬂow cytometry and
expressed as MFI. Data are mean6 SEM from eight experiments (UCMSC) or four experiments (BMMSC), except for b2-integrins when two
isolates of each type were analyzed. (D, E): UCMSC and BMMSC were treated with blocking antibodies against b1- or b3-integrin prior to per-
fusion over collagen (D) or ﬁbronectin (E) for 4 minutes at a wall shear rate of 35 s21. Data are expressed as adhesion as a percentage of
untreated mesenchymal stem cells control. Data are mean6 SEM from three experiments (UCMSC) or six experiments (BMMSC). *, p< .05;
**, p< .01 for comparison to untreated control by paired t test. Abbreviations: BMMSC, bone-marrow mesenchymal stem cells; MFI, median
ﬂuorescence intensity; MSC, mesenchymal stem cells; UCMSC, umbilical cord mesenchymal stem cells.
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Receptors Underlying MSC Adhesion to Matrix
Proteins
We ﬁrst evaluated levels of expression of b1-, b2-, or b3-
integrins. UCMSC and BMMSC showed high levels of expres-
sion of b1-integrins, low levels of b3-integrins, and no detect-
able expression of b2-integrins with no signiﬁcant differences
in expression between the cell types (Fig. 1C).
Next, we tested the effects of pretreating the MSC with
function-blocking antibodies against b1- or b3-integrins on their
adhesion to collagen and ﬁbronectin. UCMSC adhesion to colla-
gen was reduced by 90% when b1-integrin was blocked, while
blocking b3-integrins had no signiﬁcant effect (Fig. 1D). Adhesion
of BMMSC was decreased by 70% when b1-integrin was
blocked, while blocking b3-integrins reduced adhesion by 35%
(Fig. 1D). Overall, b1-integrins supported adhesion of MSC to col-
lagen, with a contribution from b3-integrins for BMMSC. Adhe-
sion of UCMSC to ﬁbronectin was inhibited almost completely by
blockade of b1-integrins, but antibody against b3-integrins had
no signiﬁcant effect (Fig. 1E). For BMMSC, blockade of b1-integ-
rins was again much more effective than blockade of b3-integrins
(Fig. 1E). Thus, b1-integrins were also the dominant receptors for
adhesion to ﬁbronectin.
Adhesion of MSC from Flowing Whole Blood to Matrix
Proteins and to Platelets
We added ﬂuorescently labeled MSC to whole blood and per-
fused the suspension over coated surfaces at a wall shear
rate of 35 s21 (the middle value of those previously tested).
Interestingly, while many UCMSC in whole blood adhered on
collagen (albeit less efﬁciently than when perfused in culture
media), very few BMMSC bound (Fig. 2A). On closer observa-
tion, UCMSC adhered in clumps (Fig. 2B). After washing out
the blood, platelet “thrombi” were observed on the collagen
and around the clumps of UCMSC (Fig. 2C). No MSC adhered
to ﬁbronectin when they were perfused in whole blood (Fig.
2D). After washing out the blood, the ﬁbronectin surface was
covered by spread platelets in a monolayer without aggre-
gates of “thrombi” (Fig. 2F). It appeared that those platelets
inhibited the MSC from binding to the ﬁbronectin itself. How-
ever, when isolated MSC were perfused over this platelet-
coated ﬁbronectin, they were able to adhere in large numbers
with the percentage of UCMSC adhering being signiﬁcantly
higher than BMMSC (Fig. 2E, 2G). Since these platelets were
presumably not fully activated as they did not form aggre-
gates from blood, TRAP was perfused to fully activate them,
and then isolated MSC were perfused. TRAP increased the
adhesion of both MSC types compared to the untreated
platelet monolayers (Fig. 2E).
Activation and Aggregation of Platelets by MSC in
Suspension
The results above showed that MSC were intrinsically able to
adhere to matrix proteins and to deposited platelets. How-
ever, in blood, this adhesion was effectively “masked,” except
when UCMSC adhered to collagen along with activated plate-
lets. We hypothesized that UCMSC adhered to platelets and
activated them in blood, while BMMSC could bind but not
activate platelets.
We thus assessed the ability of MSC to activate and
aggregate platelets directly by quantifying the change in
absorbance (or turbidity) of PRP after UCMSC or BMMSC
were added. In general, the absorbance of PRP decreases
when platelets become activated and aggregate, toward a
minimum absorbance measured for PPP. We found that absor-
bance relative to PRP decreased dramatically when UCMSC
were mixed with PRP, but not when BMMSC were added (Fig.
3A), indicating that only the UCMSC induced aggregation. The
effect is illustrated in Figure 3B, which shows the turbid
appearance of PRP mixed with BMMSC, compared to the rela-
tive clarity of PRP mixed with UCMSC.
Some stromal cells express podoplanin which can activate
platelets through their membrane receptor CLEC-2 [25, 28].
On screening a number of isolates of UCMSC and BMMSC,
we found that BMMSC did not express podoplanin but
UCMSC usually did (see, e.g., Fig. 3C). Among 14 UCMSC iso-
lates, 3 lacked expression and 11 showed positive expression
(of which 3 had bimodal distributions). Considering the immu-
nophenotype of UCMSC, all the aforementioned isolates meet
the criteria of the International Society for Cell Therapies to
be identiﬁed as MSC based on expression of MSC markers.
Bimodal isolates were subsequently sorted into podoplanin
positive and negative fractions and analyzed. Podoplanin sta-
tus following cell sorting was very stable, even after freezing
in liquid nitrogen, thawing and reculture. Moreover, expres-
sion of CD44, CD90, and CD73 and differentiation capacity
were essentially identical for positive and negative cells when
reanalyzed after fractionation (for three different isolates), or
after gating on podoplanin for unfractionated bimodal isolates
(two isolates). We also found that all isolates could be differ-
entiated regardless of podoplanin expression. While expres-
sion of podoplanin might have functional signiﬁcance (see
below), it did not appear to identify different “stemness”
among cells.
We thus tested effects of podoplanin expression on platelet
aggregation. UCMSC isolates that expressed podoplanin caused a
signiﬁcant decrease in absorbance in PRP, while podoplanin-
negative UCMSC did not (Fig. 3D). To further evaluate the mecha-
nism, human recombinant CLEC-2 protein was added to PRP and
podoplanin positive UCMSC. CLEC-2 protein signiﬁcantly reduced
the change absorbance compared to untreated controls (Fig. 3E),
indicating competitive inhibition of platelet activation.
Next, we mixed MSC with whole blood and measured the
blood platelet count. The platelet counts were signiﬁcantly
reduced when blood was mixed with podoplanin-positive
UCMSC, but not with podoplanin-negative UCMSC or with
BMMSC (Fig. 4A). In blood smears platelets aggregates could
be observed microscopically in the samples mixed with
podoplanin-positive UCMSC (Fig. 4B). We also added UCMSC
to blood from control Clec1bﬂ/ﬂ mice or mice deﬁcient in
CLEC-2. Expression of CLEC-2 on platelets from the latter was
evaluated by ﬂow cytometry and showed some variation; only
those with <5% platelets expressing CLEC-2 were analyzed
further. There was a marked drop in platelet count when
podoplanin-positive UCMSC were added to blood from the
control mice, but not when they were added to blood from
mice deﬁcient in platelet CLEC-2 (Fig. 4C).
Receptors Underlying UCMSC Adhesion to Platelets
and in Whole Blood
When UCMSC were perfused over a platelet monolayer
deposited onto ﬁbronectin, pretreatment with antibody
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Figure 2. Adhesion of mesenchymal stem cells (MSC) from ﬂowing blood to collagen and ﬁbronectin and to deposited platelets.
UCMSC or BMMSC were suspended in blood or in culture medium, and perfused over collagen or ﬁbronectin-coated surfaces at a wall
shear rate 35 s21 for 4 minutes. (A): Adhesion to collagen. Analysis of variance (ANOVA) showed a signiﬁcant effect of cell type and of
suspending medium on binding to collagen (both p< .01). (B, C): Fluorescence and phase contrast micrographs of the same ﬁeld of
view showing clumps of UCMSC labeled with cell tracker green, bound on a collagen surface after perfusion and washout of blood. (D):
Adhesion to ﬁbronectin. ANOVA showed a signiﬁcant effect of suspending medium on binding to ﬁbronectin (p< .01). (E): Adhesion of
isolated BMMSC or UCMSC to platelet monolayers which had previously been deposited from blood onto ﬁbronectin, with or without
subsequent treatment of the platelets with TRAP. ANOVA showed a signiﬁcant effect of cell type and of TRAP on adhesion (p< .01 in
each case). (F): Phase contrast micrograph of the platelet monolayer deposited onto ﬁbronectin after perfusion and washout of blood.
(G): Phase contrast micrograph of UCMSC adhered from ﬂow on a platelet monolayer previously deposited on ﬁbronectin. Data are
mean6 SEM from three experiments, except in (A) where adhesion from ﬂowing blood was tested in four experiments. **, p< .01 com-
pared to respective MSC tested in culture medium by Bonferroni test. Abbreviations: BMMSC, bone-marrow mesenchymal stem cells;
TRAP, thrombin receptor activating peptide; UCMSC, umbilical cord mesenchymal stem cells.
against b1-integrin caused >90% reduction in the number
adherent; a smaller decrease was observed with antibody
against b3-integrin (Fig. 5A). When UCMSC were mixed with
PRP, blocking b1-integrin completely inhibited the decrease in
absorbance (Fig. 5B). Pretreatment of platelets with antibody
against aIIbb3-integrin also ablated the aggregation response
Figure 3. Differential effects of mesenchymal stem cells on platelet aggregation and role of podoplanin. (A): UCMSC or BMMSC were
mixed with PRP for 20 minutes at 378C. Platelet aggregation was quantiﬁed by a decrease in absorbance compared to PRP. (B): Repre-
sentative images of PRP after mixing with UCMSC or BMMSC, with UCMSC decreasing the turbidity compared to BMMSC. (C): UCMSC
and BMMSC were stained with an anti-podoplanin (PDPN, blue) antibody or nonspeciﬁc control (red) and analyzed by ﬂow cytometry.
Different levels of expression of PDPN were observed on UCMSC, while no expression was detected on BMMSC. (D): PDPN positive
(PDPN1) or negative (PDPN2) UCMSC were stirred with PRP and platelet aggregation was quantiﬁed by a decrease in absorbance com-
pared to PRP alone. (E): PRP was either untreated or treated with recombinant human CLEC2 (rhCLEC2) prior to stirring with UCMSC
and aggregation was quantiﬁed by a decrease in absorbance compared to PRP. Data are mean6 SEM from 6 (A), 4 (B), or 10 (C) experi-
ments. **, p< .01 by unpaired t test (A, D) or paired t test (E). Abbreviations: BMMSC, bone-marrow mesenchymal stem cells; PRP,
platelet-rich plasma; UCMSC, umbilical cord mesenchymal stem cells.
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(Fig. 5B). It was notable that microscopic observation of
UCMSC added to PRP in the presence of anti-aIIbb3-integrin
did show single platelets attached to the MSC, indicating that
direct adhesion of platelets to MSC was not through this
receptor. Thus, b1-integrins were required for interaction of
UCMSC with platelets and platelet-platelet aggregation oper-
ated through activation of aIIbb3-integrin.
When UCMSC were perfused over collagen in whole
blood, adhesion was reduced by >80% when UCMSC were pre-
treated with antibody against b1-integrin (Fig. 5C). Platelet depo-
sition on the collagen was not modiﬁed, but the UCMSC did not
adhere to the platelets. There was a lesser nonsigniﬁcant effect
with antibody against b3-integrin (Fig. 5C). We then tested the
effect of treating platelets with antibodies against GpIb or
aIIbb3-integrin. The former partially reduced platelet attachment
to the surface and also adhesion of UCMSC (Fig. 5C). The latter
left only a few single platelets on the collagen surface and
completely abolished adhesion of UCMSC (Fig. 5C). In this case,
the platelet-coated MSC presumably could not bind direct to the
exposed collagen. We tried blocking b1-integrin on UCMSC in
combination with blockade of platelet aIIbb3-integrin, which
should leave “bare” MSC to ﬂow across nearly “bare” collagen.
A few single spherical MSC were observed to adhere, but the
b1-integrin blockade would also inhibit MSC adhesion to the col-
lagen (Fig. 5C).
Fate of MSC and Effect on Platelet Count When
Infused into Mice
UCMSC, BMMSC, or PBS were injected into C57BL/6 mice via
the tail vein. Injection of UCMSC caused a marked (40%)
drop in circulating blood platelet count at 4 hours, which was
maintained at 24 hours, but recovered by 48 hours (Fig. 6A).
There were no signiﬁcant changes in platelet count in mice
that had received BMMSC or PBS. The decrease in platelet
count was signiﬁcantly greater after infusion of podoplanin-
positive UCMSC than podoplanin-negative UCMSC (Fig. 6B).
Fluorescently labeled MSC were imaged in live, anesthetized
mice 4 and 24 hours after infusion, using the IVIS in vivo
imaging system. For both cell types, dominant signals were
observed from a location below the thorax suggesting that
visceral organs such as liver and spleen contained major pop-
ulations (Fig. 6C). Since the signal from organs in intact ani-
mals will inevitably be inﬂuenced by the optical properties of
the overlying tissue, to increase sensitivity, major organs were
retrieved after termination of the experiment at 1 or 24 hours
after injection of MSC and imaged separately. Clear signals
were evident from lung, liver, and spleen at both time points
(e.g., Fig. 6D). There was no detectable difference in intensity
of ﬂuorescence between the UCMSC and BMMSC.
We next infused podoplanin-positive UCMSC into the mice
expressing or lacking CLEC-2. As shown in Figure 6E, 4 hours after
infusion, platelet count was reduced reliably in Clec1bﬂ/ﬂ control
mice. However, results were highly variable in the Clec1bﬂ/ﬂ PF4-
Cre mice lacking CLEC2, with only 3 out of 11 mice maintaining
an undisturbed platelet count (98% of preinfusion value).
DISCUSSION
We report the ﬁrst studies of the adhesion of MSC from ﬂow,
including comparison of isolated cells with those in blood,
Figure 4. Effects of MSC on platelet counts in blood in vitro.
(A): Whole human blood was stirred with podoplanin positive
(PDPN1) UCMSC, podoplanin negative (PDPN2) UCMSC or
BMMSC and platelet count was measured. Analysis of variance
showed a signiﬁcant effect of treatment on platelet count
(p< .01). *, p< .05, **, p< .01 by Bonferroni test. Data are
mean6 SEM from six experiments. (B): Representative images of
H&E stained blood ﬁlms made after the aggregation assay for
blood alone or blood stirred with PDPN1 UCMSC using a bright-
ﬁeld microscopy at 340 magniﬁcation. (C): Blood from clec1bﬂ/ﬂ
or clec1bﬂ/ﬂ PF4-cre mice was mixed with PDPN1 UCMSC and
platelet count was assessed and expressed relative to untreated
blood. **, p< .01 by unpaired t test. Data are mean6 SEM from
three experiments. Abbreviations: BMMSC, bone-marrow mesen-
chymal stem cells; MSC, mesenchymal stem cells; UCMSC, umbili-
cal cord mesenchymal stem cells.
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and comparison of MSC from BM or UC. We made the sur-
prising discoveries that both MSC types were captured by
matrix proteins (collagen and ﬁbronectin) more efﬁciently
than by puriﬁed selectins, and that adhesion was massively
altered when cells were perfused in blood. In blood, BMMSC
barely adhered at all, while UCMSC bound to collagen, but
not ﬁbronectin, along with platelets in clumps. A key ﬁnding
was that while both types of MSC bound to platelets, only
UCMSC caused marked activation, driving platelet-platelet
aggregation. The difference was attributable to expression of
podoplanin on UCMSC and not on BMMSC. Consequently,
when injected into mice, podoplanin-expressing UCMSC
caused a marked reduction in platelet count, while BMMSC
did not. Thus, when MSC are infused therapeutically, interac-
tion with platelets is likely to inﬂuence their deposition into
tissue, with expression of podoplanin adding a potential
thrombotic effect.
Adhesion from ﬂow may be a critical step for the recruit-
ment of stem cells for vascular protection, although the
mechanisms are still open to debate [13]. One study found
adhesion of BMMSC to endothelial cells at shear stress 0.1 Pa
(equivalent to 140 s21) [18], but we and others [8, 17] found
that shear needed to be reduced to about 0.01 Pa (14 s21) to
allow capture to endothelial cells. Here, MSC could bind to
matrix proteins, collagen, and ﬁbronectin much more effec-
tively than selectins. b1-integrins played the major role for
attachment of MSC to both proteins while for BMMSC b3-
integrins also contributed. Others have reported that BMMSC
use b1-integrin family members to bind to collagen and ﬁbro-
nectin under static conditions [29]. Expression of adhesion
molecules on MSC may be dependent on their source and
the isolation method [30]. However, we observed no differ-
ence in the surface expression of b1- and b3-integrins that
could account for UCMSC adhering more efﬁciently than
BMMSC. Our results suggest that MSC would be more likely
to adhere in a damaged vessel with exposed subendothelial
matrix than in an inﬂamed vessel with intact endothelium.
When added to blood, MSC were outnumbered by plate-
lets by about 1,000:1. Both types of MSC may have attracted
platelet satellites, but UCMSC must have induced extensive
higher order aggregation in order to reduce platelet count. It
seems that BMMSC coated with inactive platelets could not
attach to the platelets on the ﬁbronectin or collagen. How-
ever, UCMSC could activate bound platelets and then join in
large structures on collagen, but not ﬁbronectin where the
“inactive” platelet monolayer did not capture them. For the
Figure 5.
Figure 5. Roles of adhesion receptors in binding of umbilical
cord mesenchymal stem cells (UCMSC) to platelets, induction of
platelet aggregation by UCMSC or binding of UCMSC to collagen
from whole blood. (A): Effect of pretreatment with antibodies
against b1- or b3-integrin on adhesion of UCMSC, suspended in
culture medium, to platelet monolayers that had been deposited
from whole blood onto ﬁbronectin. Data are mean6 SEM from
three experiments with adhesion expressed relative to untreated
controls. *, p< .05 and **, p< .01 compared to untreated con-
trol by paired t test. (B): Effect of pretreating UCMSC with anti-
body against b1-integrin, or treating PRP with antibody against
aIIbb3-integrin, on aggregation of platelets after UCMSC were
mixed with PRP. Data are mean6 SEM from three experiments
with absorbance expressed relative to PRP alone. **, p< .01
compared to PRP alone by paired t test. (C): Effect of pretreating
UCMSC with antibodies against b1-integrin (n5 9) or b3-integrin
(n5 3), or of treating blood with antibody against GpIb (n5 3) or
aIIbb3-integrin (n5 6) or both (n5 4) on adhesion of UCMSC
perfused in whole blood over collagen. Data are mean6 SEM
from n experiments expressed relative to adhesion for untreated
controls. *, p< .05 and **, p< .01; 1, borderline signiﬁcance,
p< .07; compared to untreated control by paired t test. Abbrevia-
tion: PRP, platelet-rich plasma.
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Figure 6. Fate of MSC infused into mice: effects on blood platelet counts and deposition in tissues. (A): Effects of infused MSC on
blood platelet counts. Wild-type mice were injected with phosphate-buffered saline, UCMSC, or BMMSC, and platelet count measured
before (t5 0) 4, 24, 48, or 72 hours after injection. Analysis of variance (ANOVA) showed a signiﬁcant effect of treatment and of time
(p< .01 in each case). **, p< .01 compared to PBS or to UCMSC by Bonferroni test. Data are mean6 SEM from at least 9 mice for
t5 0, at least 6 mice for t5 4 and at least 7 mice for t5 24, and 2–4 mice at 48 or 72 hours. (B): Comparison of effects of
podoplanin-positive (PDPN1) or negative (PDPN2) UCMSC on blood platelet counts. Wild-type mice were injected with PDPN1 MSC
(n5 17) or PDPN2 MSC (n5 12) and platelet count measured before (t5 0), 4 or 24 hours after injection. ANOVA showed that there is
a signiﬁcant effect of cell type and time (p< .01 in each case). *, p< .05 by t test compared to PDPN2. Data are mean6 SEM from (n)
mice expressed as a percentage of the number of platelets before injection. (C, D): IVIS images of whole anesthetized mice 4 hours
after injection with UCMSC or BMMSC (C), or of isolated liver, lungs, and spleen of two different mice 1 hour after injection (D). (E):
Effects of infused podoplanin-positive PDPN1 UCMSC on blood platelet counts in mice expressing or lacking CLEC-2. Clec1bﬂ/ﬂ mice
(control, n5 9) or Clec1bﬂ/ﬂ PF4-Cre (n5 11) mice were injected with MSC, and platelet count measured before t5 0 and 4 after injec-
tion. Individual data (and median) are shown, expressed as a percentage of the number of platelets before injection. Abbreviations:
BMMSC, bone-marrow mesenchymal stem cells; MSC, mesenchymal stem cells; PBS, phosphate-buffered saline; UCMSC, umbilical cord
mesenchymal stem cells.
UCMSC, adhesion to platelets was via b1-integrins, with sub-
sequent platelet aggregation supported by aIIbb3-integrin,
which is known to mediate platelet-platelet aggregation
driven by a number of agonists [31]. Since UCMSC bound
both collagen and platelets through b1-integrins, it was difﬁ-
cult to devise a blocking strategy that allowed direct binding
of UCMSC to collagen in blood. While platelet attachment to
collagen could be inhibited by blocking aIIbb3-integrin or
GpIb, this left UCMSC in blood coated with platelets that
could not bind to the collagen either. Combination of platelet
and b1-integrin blockade would leave collagen and the
UCMSC surfaces vacant, but they would not be able to bind
each other. These results are consistent with the scenario
illustrated in Figure 7, where we propose a sequence of
events if MSC injected into blood are exposed to collagen or
ﬁbronectin in damaged vessels.
In vivo, platelets facilitated BMMSC homing to lung vascula-
ture in a rat model of pulmonary arterial hypertension [20].
Intravital microscopy showed an association between infused
MSC, leukocytes, and platelets at the site of lipopolysaccharide-
induced dermal inﬂammation in mice while platelet depletion
decreased the trafﬁcking of MSC to the site [19]. Moreover,
Langer et al. found that platelets attached to endothelial cells
in vitro could increase BMMSC adhesion, and that injected
BMMSC became attached to damaged arteries via platelets
[32]. In our experiments, during washout of blood, we observed
small, round leukocytes rolling across platelets bound to colla-
gen, and also some attached to the clumps of platelets and
UCMSC. The numbers were not great enough to obstruct access
of the MSC themselves to the collagen, but MSC may have facil-
itated localization of the leukocytes. The previous studies in
vivo all used BMMSC. Our studies raised two questions—what
might be the basis of the differences in interaction with plate-
lets between BMMSC and UCMSC and what would happen,
comparatively, if the two MSC were infused?
We did not observe marked differences in the locations of
infused ﬂuorescently labeled UCMSC or BMMSC tracked used
live imaging. Most cells from either source were found in lungs,
liver, and spleen. These observations are as expected from pre-
vious reports, showing, for example, early deposition in lungs
after injection [33, 34], where sequestration may result from
mechanical trapping of the large cells (20 mm diameter for
our dissociated UCMSC or BMMSC). However, we did ﬁnd that
there were marked reductions in circulating platelet count
when UCMSC were infused, but not BMMSC. This was consis-
tent with the ability of UCMSC to reduce platelet count when
mixed with human or mouse blood in vitro. Screening for differ-
ences in surface proteins on the MSC, we found that most
UCMSC isolates expressed podoplanin, which is a ligand for the
platelet receptor CLEC-2 and known to activate platelets [25].
Only the podoplanin-positive UCMSC caused aggregation in
PRP and a drop in platelet count in blood. Aggregation was
reduced in the presence of soluble recombinant CLEC-2, while
platelet count was unaffected if UCMSC were mixed with blood
from mice lacking CLEC-2 expression. When UCMSC were
injected into mice lacking expression of CLEC-2, we found that
the response in platelet count was highly variable compared to
control mice; only 3 out of 10 mice showed no decrease, but 7
out of 12 knockout mice showed reductions between 30% and
70%. Thus, podoplanin-CLEC-2 interaction clearly drove platelet
activation, aggregation, and reduction in count in blood in vitro.
However, here, and to a lesser extent in other recent studies in
Figure 7. Interaction between MSC and platelets in blood and effects on adhesion when perfused over matrix proteins. In blood,
BMMSC bind platelets which are inactive and effectively shield them so that they do not adhere to platelets deposited on ﬁbronectin
or collagen. UCMSC express podoplanin (PDPN) so that they not only bind platelets but also activated them through CLEC-2. They do
not adhere to the minimally activated platelets on ﬁbronectin but do bind with activated platelets on collagen. In the ﬂowing blood,
the UCMSC with bound platelets may be able to drive wider-spread activation and aggregation of platelets, that leads to a reduction in
platelet count in vitro or in vivo. Abbreviations: BMMSC, bone-marrow mesenchymal stem cells; MSC, mesenchymal stem cells; UCMSC,
umbilical cord mesenchymal stem cells.
Sheriff, Alanazi, Ward et al. 11
www.StemCells.com VC 2018 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
our facility [35], the responses to podoplanin ligation in the
Clec1bﬂ/ﬂ PFcre model of CLEC2 reduction were variable in
vivo. We checked expression of CLEC-2 on platelets, and found
less than 5% of platelets from Clec1bﬂ/ﬂ PFcre mice to be posi-
tively labeled by antibody. Residual platelet CLEC-2 may have
induced an activation response through podoplanin on UCMSC,
but there might also be another ligand for podoplanin active in
vivo, or UCMSC may have had additional differences to the
BMMSC which inﬂuenced platelet count in vivo.
Overall, functional studies used six different isolates of
BMMSC (from a commercial source) and 10 isolates of
UCMSC (derived in-house). The isolates, their passage num-
bers, podoplanin status, and effects are listed in Supporting
Information Table S1. Effects clearly correlate with podoplanin
expression as discussed above. Passage number does not
appear to be a factor in differences between BMMSC and
UCMSC, or in podoplanin expression in UCMSC. Podoplanin
expression remained stable in isolates, and after bimodal iso-
lates were fractionated and returned to culture. The cause of
variation in expression of podoplanin between UCMSC isolates
is unresolved as donors were anonymous, but a systematic
prospective study of this issue with appropriate ethical con-
sent might be of interest. This may be important, because a
number of reports have questioned compatibility of MSC with
blood, where they may induce inﬂammatory or coagulation
responses in vitro and if infused [36–39]. Those studies used
BMMSC or adipose-derived MSC (ADMSC), and indicated that
responses increased with passaging and varied between sour-
ces, with ADMSC presenting tissue factor and inducing coagu-
lation. BMMSC studied here did not express podoplanin at
any passage, and the status of ADMSC is unknown in this
context. UCMSC may have particular reaction with platelets,
which depends on the donor but not evidently on passage
number. It appears, however, that MSC for clinical use should
be screened for interactions with blood elements that could
inﬂuence safety of therapeutic infusion.
CONCLUSION
The ability of MSC to differentiate into organ-speciﬁc cells has
led to their use for regenerative therapy [40]. MSC are also
able to suppress immune responses through effects of leuko-
cytes and endothelial cells [6–8, 11, 26]. Therapeutic use of
MSC via infusion may depend on their ability to adhere in
vessels of target organs and on interactions with platelets
which may facilitate “homing” to inﬂamed tissue [19, 20, 32].
We found that the origins of the MSC and their expression of
podoplanin had impact on their behavior in the blood. Both
MSC types studied here were able to bind platelets, which
might facilitate attachment to damaged or inﬂamed vessels,
although satellites formed by inactive platelets could “hide”
the MSC in some circumstances. On the other hand, platelet
activation by MSC in the circulating blood could cause throm-
bus formation and/or reduction in platelet count. There is
thus a potential conﬂict between efﬁcacy in localization and
risk of thrombosis, associated with properties of MSC from
different origins, which remains to be resolved.
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